NDC 65145-119

Prochlorperazine Edisylate

Prochlorperazine Edisylate

Prochlorperazine Edisylate is a Intramuscular; Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Caplin Steriles Limited. The primary component is Prochlorperazine Edisylate.

Product ID65145-119_27f87467-4ff3-4102-b3da-cddb5cf62abb
NDC65145-119
Product TypeHuman Prescription Drug
Proprietary NameProchlorperazine Edisylate
Generic NameProchlorperazine Edisylate
Dosage FormInjection
Route of AdministrationINTRAMUSCULAR; INTRAVENOUS
Marketing Start Date2021-05-03
Marketing CategoryANDA /
Application NumberANDA214379
Labeler NameCaplin Steriles Limited
Substance NamePROCHLORPERAZINE EDISYLATE
Active Ingredient Strength5 mg/mL
Pharm ClassesPhenothiazine [EPC],Phenothiazines [CS]
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 65145-119-25

25 VIAL in 1 CARTON (65145-119-25) > 2 mL in 1 VIAL (65145-119-01)
Marketing Start Date2021-05-03
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "Prochlorperazine Edisylate" or generic name "Prochlorperazine Edisylate"

NDCBrand NameGeneric Name
0641-0491Prochlorperazine EdisylateProchlorperazine Edisylate
0641-6135Prochlorperazine EdisylateProchlorperazine Edisylate
14789-700Prochlorperazine EdisylateProchlorperazine Edisylate
23155-294Prochlorperazine EdisylateProchlorperazine Edisylate
23155-497PROCHLORPERAZINE EDISYLATEPROCHLORPERAZINE EDISYLATE
23155-523Prochlorperazine EdisylateProchlorperazine Edisylate
43066-090PROCHLORPERAZINE EDISYLATEprochlorperazine edisylate
50090-4548Prochlorperazine EdisylateProchlorperazine Edisylate
55154-4183Prochlorperazine EdisylateProchlorperazine Edisylate
65145-119Prochlorperazine EdisylateProchlorperazine Edisylate
67457-640prochlorperazine edisylateprochlorperazine edisylate
70860-778Prochlorperazine Edisylateprochlorperazine edisylate
72572-580Prochlorperazine EdisylateProchlorperazine Edisylate

© 2021 FDA.report
This site is not affiliated with or endorsed by the FDA.